Table 3.
Response of patients treated with venetoclax and decitabine or azacytidine
| Response | ||||
|---|---|---|---|---|
| Response Category | All patients (N = 50)A |
Decitabine-venetoclax (N = 30) |
Azacitidine-venetoclax (N = 20) |
Significance |
| Complete remission (CR) | 10 (20.0) | 5 (16.7) | 5 (25.0) | p = 0.494 |
| Complete remission with incomplete hematologic recovery (CRi) | 10 (20.0) | 5 (16.7) | 5 (25.0) | p = 0.494 |
| Composite complete remission (CR + CRi) | 20 (40.0) | 10 (33.3) | 10 (50.0) | p = 0.258 |
| Composite complete remission by ELN 2022 cytogenetic risk category – no. (%) | ||||
| FavorableB | 3 (37.5) | 3 (42.9) | 0 (0) | p > 0.999 |
| IntermediateC | 4 (36.4) | 2 (33.3) | 2 (40.0) | p > 0.999 |
| AdverseD | 13 (41.9) | 5 (29.4) | 8 (53.3) | p = 0.157 |
| Composite complete remission by disease status – no. (%) | ||||
| RelapsedE | 9 (45.0) | 4 (36.4) | 5 (55.6) | p = 0.653 |
| RefractoryF | 11 (36.7) | 6 (31.6) | 5 (45.5) | p = 0.696 |
| Composite complete remission with respect to hypomethylating agent exposure – no. (%) | ||||
| Prior hypomethylating agentG | 2 (25.0) | |||
| No prior hypomethylating agentH | 18 (42.9) | |||
Fifty of 57 patients were evaluable for response: 30 in the decitabine cohort and 20 in the azacitidine cohort
In the favorable risk category, seven patients in the decitabine cohort and one in the azacitidine cohort were evaluable
In the intermediate risk category, six patients in the decitabine cohort and five in the azacitidine cohort were evaluable
In the adverse risk category, 17 patients in the decitabine cohort and 14 in the azacitidine cohort were evaluable
In the relapsed setting, 11 patients in the decitabine cohort and nine in the azacitidine cohort were evaluable
In the refractory setting, 19 patients in the decitabine cohort and 11 in the azacitidine cohort were evaluable
Response was evaluable in eight of 11 patients exposed to a hypomethylating agent
Response was evaluable in 42 of 46 patients with no prior hypomethylating agent exposure